Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
While Vertex has other prospects within its Hill End and Hargraves project in the gold M&A hotspot of the Lachlan Fold Belt, getting to production from the super high-grade 419,000t at 16.72g/t Reward ...
Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88. The stock’s fifty day simple moving average is $445.93 and its 200 day simple moving average is $467.13.
Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...
Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.
We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO ... who have the most severe form of the condition.
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove safe and effective for chronic pain.
BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...
Almost every aspect of modern life is affected by our connectivity to the Web. On those rare occasions when my internet provider has an outage, life seems to come to a standstill. Everything from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback